x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Psychopharmacology and Psychiatry Updates

Psychopharmacology Institute

Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.

health & fitness medicine

All Episodes

10:56

INTEGRATE Guidelines: Standardizing Schizophrenia...

Psychopharmacology and Psychiatry Updates ·

2026/01/11

In this episode, we explore the newly published INTEGRATE guidelines—the first truly international algorithm for schizophrenia treatment. Should clozapine be started after just 12 weeks? When are long-acting injectables appropriate for first-episode patients? Discover how these guidelines aim to standardize quality care worldwide. Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 77 INTEGRATE: New Schizophrenia

en

11:16

Pharmacogenetics: Separating Science from Marketing

Psychopharmacology and Psychiatry Updates ·

2026/01/06

In this episode, we explore the practical role of genetic testing in psychiatry with Dr. Chris Aiken. Which genetic tests actually matter in clinical practice? We cut through the marketing hype to reveal the three essential pharmacokinetic tests and FDA requirements that can prevent serious adverse events in your patients. Faculty: Chris Aiken, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: The Role of Genetic Testing in Psychiatry Pharmacogenetic Tests That

en

12:24

Lithium vs. Quetiapine: Augmenting...

Psychopharmacology and Psychiatry Updates ·

2026/01/01

In this episode, we explore a head-to-head comparison of lithium versus quetiapine augmentation for treatment-resistant depression. When patients have failed multiple antidepressants, which augmentation strategy offers the best balance of efficacy and tolerability? We examine real-world data tracking symptom burden and side effects over an entire year. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 76 Treatment-Resistant

en

08:48

Postpartum Psychopharmacology: Breastfeeding and...

Psychopharmacology and Psychiatry Updates ·

2025/12/27

In this episode, we explore pharmacologic strategies for postpartum psychosis with insights from Dr. Lauren Osborne, focusing on a critical clinical question: Can we safely use mood stabilizers like lithium in breastfeeding mothers with bipolar disorder? Discover evidence-based guidance for navigating this high-stakes decision when maternal mental health hangs in the balance. Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Understanding

en

11:44

Fast-Acting Relief: Neurosteroids for Postpartum...

Psychopharmacology and Psychiatry Updates ·

2025/12/22

In this episode, we explore brexanolone and zuranolone—the first FDA-approved medications specifically for postpartum depression. How do these neurosteroid-based treatments work differently than traditional antidepressants, and could they offer relief in just days rather than weeks? Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Understanding Postpartum Mood Disorders: A Comprehensive Guide The Role of Brexanolone and Zuranolone in

en

14:38

Lumateperone for Depression with Mixed Features: New...

Psychopharmacology and Psychiatry Updates ·

2025/12/17

In this episode, we explore lumateperone for treating major depressive episodes with mixed features – that challenging presentation where patients experience depression alongside racing thoughts and restlessness. Can we effectively treat both the despair and the activation without triggering mania? Dr. Kristin Raj examines the evidence and clinical implications for this understudied population. Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME:

en

14:07

Antidepressants and Breastfeeding: Safety Considerations

Psychopharmacology and Psychiatry Updates ·

2025/12/12

In this episode, we explore pharmacologic treatment for postpartum depression in breastfeeding mothers. Can psychiatric medications be safely used while nursing? Dr. Lauren Osborne explains how nearly all antidepressants are compatible with breastfeeding, why postpartum women may respond faster to treatment, and how to choose the right medication. Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Understanding Postpartum Mood Disorders: A

en

13:50

QT Prolongation and Psychiatric Medication: A Cardiac...

Psychopharmacology and Psychiatry Updates ·

2025/12/07

In this episode, we explore a new study examining whether antidepressants and antipsychotics truly increase the risk of torsades de pointes, a potentially fatal cardiac arrhythmia. What does the evidence say about using multiple psychiatric medications together, and when should we actually be concerned? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 75 Torsades de Pointes: Impact of Antidepressants and Antipsychotics

en

13:39

Distinguishing Postpartum OCD from Psychosis

Psychopharmacology and Psychiatry Updates ·

2025/12/02

In this episode, we explore the critical distinction between postpartum OCD and postpartum psychosis. Dr. Lauren Osborne reveals why accurate diagnosis matters for treatment and safety. Did you know intrusive thoughts about infant harm don't actually indicate elevated risk in OCD, but do in psychosis? Faculty: Lauren Osborne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Understanding Postpartum Mood Disorders: A Comprehensive Guide Distinguishing Postpartum

en

11:13

Do SSRI Side Effects Improve Over Time?

Psychopharmacology and Psychiatry Updates ·

2025/11/27

In this episode, we examine groundbreaking research that challenges the widespread clinical belief that SSRI side effects improve with time. Using data from the landmark STAR*D trial, we explore which patients actually experience side effect resolution and which face worsening symptoms. Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 75 Do SSRI Side Effects Improve Over Time?

en

07:43

Beyond Lithium Monotherapy: Evidence-Based...

Psychopharmacology and Psychiatry Updates ·

2025/11/22

In this episode, we explore evidence-based strategies for augmenting lithium when monotherapy fails in acute mania. Why is quetiapine the preferred add-on to valproate, despite decades of clinical tradition favoring anticonvulsants? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: An Update on Bipolar Mania Algorithm Augmenting With SGAs After Unsatisfactory Response to Lithium in Bipolar Mania

en

13:42

Choosing First-Line Antipsychotics: Considering Violence

Psychopharmacology and Psychiatry Updates ·

2025/11/17

In this episode, we explore a groundbreaking Mayo Clinic algorithm that revolutionizes antipsychotic selection for first-episode psychosis. Should the presence of violence completely change your medication choice strategy? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 75 Schizophrenia Algorithm: Selecting an Antipsychotic for First Episodes

en

15:05

Beyond Antipsychotics: Using Lithium in Mania

Psychopharmacology and Psychiatry Updates ·

2025/11/12

In this episode, we challenge conventional prescribing by exploring why lithium should be the first-line treatment for acute classic mania, despite widespread use of antipsychotics. Dr. David Osser presents evidence-based arguments for lithium's unique neuroprotective benefits and long-term efficacy. Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: An Update on Bipolar Mania Algorithm Lithium for Bipolar Mania Without Mixed Features

en

11:12

Trazodone vs. Doxepin vs. Melatonin: Comparing...

Psychopharmacology and Psychiatry Updates ·

2025/11/07

In this episode, we explore a head-to-head comparison of trazodone, doxepin, and melatonin for treating insomnia when benzodiazepines are off the table. Which non-benzodiazepine sleep aid offers the best balance of effectiveness and tolerability in real-world psychiatric patients? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 74 Melatonin, Trazodone, or Doxepin for Sleep Disorders

en

11:40

Beyond Monotherapy: Mixed Episode Management

Psychopharmacology and Psychiatry Updates ·

2025/11/02

In this episode, we explore the critical decision of when to add lithium or valproate to second-generation antipsychotics in mixed manic episodes. Should you rush to combination therapy under managed care pressure, or does patience with strategic benzodiazepine bridging lead to better outcomes? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: An Update on Bipolar Mania Algorithm Choosing Between Valproate or Lithium Augmentation for Bipolar

en

08:58

Old Drug, New Perspectives: Disulfiram's and...

Psychopharmacology and Psychiatry Updates ·

2025/10/28

In this episode, we explore a provocative argument for reconsidering disulfiram as a first-line treatment for alcohol use disorder. Could this decades-old medication, often dismissed as outdated and dangerous, actually be more effective than newer alternatives when used in appropriately selected patients? Faculty: David Gorelick, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 74 Alcohol Use Disorder: Should Disulfiram Be First-Line?

en

13:52

Quetiapine vs. Lithium in Mixed Bipolar States

Psychopharmacology and Psychiatry Updates ·

2025/10/23

In this episode, we explore the complex pharmacological management of mixed mania, a challenging bipolar presentation affecting up to 40% of manic episodes. Why do traditional mood stabilizers like lithium fall short, and which second-generation antipsychotics emerge as first-line treatments for this dual-symptom condition? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.5 CME: Lithium: How to Manage Dosage and Side Effects Managing Renal Side

en

17:19

Psychedelic-Assisted Therapy: Redefining Treatment

Psychopharmacology and Psychiatry Updates ·

2025/10/18

In this episode, we explore psychedelic-assisted therapy in clinical practice, examining how these treatments differ fundamentally from traditional pharmacotherapy. Can psychiatrists reconcile mystical experiences with evidence-based medicine while navigating the complex therapeutic paradigm of preparation, 8-hour sessions, and integration work? Faculty: Franklin King, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: Use of Psychedelic Drugs in Psychiatry

en

13:50

Lurasidone's Therapeutic Window: Is Less More?

Psychopharmacology and Psychiatry Updates ·

2025/10/13

In this episode, we explore groundbreaking research revealing that lower doses of lurasidone (40-60mg) may be more effective for bipolar depression than higher doses. Could we be over-medicating our patients when the sweet spot for both efficacy and tolerability lies in this unexpected lower range? Faculty: Kristin Raj, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 74 Lurasidone for Bipolar Depression: What Is the Optimal Dose?

en

11:30

Beyond Black Box Warnings: Choosing Antipsychotics in...

Psychopharmacology and Psychiatry Updates ·

2025/10/08

In this episode, we explore a compelling comparison between olanzapine and risperidone for managing behavioral symptoms in dementia patients. Are the delusions we see in Alzheimer's disease actually true delusions, or something entirely different that requires a new treatment approach? Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CME: Quick Take Vol. 73 Alzheimer’s Disease: Olanzapine vs. Risperidone for BPSD

en

425 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown